Ardelyx, Inc. (ARDX)
ARDX Stock Price Chart
Explore Ardelyx, Inc. interactive price chart. Choose custom timeframes to analyze ARDX price movements and trends.
ARDX Company Profile
Discover essential business fundamentals and corporate details for Ardelyx, Inc. (ARDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2014
Employees
395.00
Website
https://www.ardelyx.comCEO
Michael G. Raab
Description
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
ARDX Financial Timeline
Browse a chronological timeline of Ardelyx, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$0.05, while revenue estimate is $125.14m.
Earnings released on 30 Apr 2026
EPS came in at -$0.15 falling short of the estimated -$0.13 by -15.38%, while revenue for the quarter reached $94.47m , beating expectations by +1.82%.
Earnings released on 19 Feb 2026
EPS came in at $0.02 matching the estimated $0.02, while revenue for the quarter reached $125.22m , beating expectations by +6.07%.
Earnings released on 30 Oct 2025
EPS came in at -$0.00 surpassing the estimated -$0.06 by +93.32%, while revenue for the quarter reached $110.33m , missing expectations by -7.33%.
Earnings released on 4 Aug 2025
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $97.66m , beating expectations by +3.21%.
Earnings released on 1 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.10 by -70.00%, while revenue for the quarter reached $74.11m , missing expectations by -6.71%.
Earnings released on 20 Feb 2025
EPS came in at $0.02 matching the estimated $0.02, while revenue for the quarter reached $116.13m , beating expectations by +55.79%.
Earnings released on 31 Oct 2024
EPS came in at -$0.00 surpassing the estimated -$0.05 by +93.14%, while revenue for the quarter reached $98.24m , missing expectations by -9.51%.
Earnings released on 1 Aug 2024
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $73.22m , beating expectations by +33.08%.
Earnings released on 2 May 2024
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $46.02m , beating expectations by +26.44%.
Earnings released on 22 Feb 2024
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $34.36m , beating expectations by +0.39%.
Earnings released on 31 Oct 2023
EPS came in at $0.03 surpassing the estimated -$0.11 by +127.27%, while revenue for the quarter reached $56.39m , beating expectations by +79.65%.
Earnings released on 2 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%, while revenue for the quarter reached $22.33m , beating expectations by +46.25%.
Earnings released on 3 May 2023
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $11.37m , beating expectations by +7.25%.
Earnings released on 2 Mar 2023
EPS came in at $0.06 surpassing the estimated $0.00 by +6.09k%, while revenue for the quarter reached $44.18m , beating expectations by +90.63%.
Earnings released on 3 Nov 2022
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $4.99m , beating expectations by +27.14%.
Earnings released on 4 Aug 2022
EPS came in at -$0.19 matching the estimated -$0.19, while revenue for the quarter reached $2.53m , beating expectations by +13.73%.
Earnings released on 5 May 2022
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $468.00k , missing expectations by -46.51%.
Earnings released on 28 Feb 2022
EPS came in at -$0.31 falling short of the estimated -$0.25 by -24.00%, while revenue for the quarter reached $1.03m , beating expectations by +17.53%.
Earnings released on 12 Nov 2021
EPS came in at -$0.42 falling short of the estimated -$0.34 by -23.53%, while revenue for the quarter reached $1.17m , beating expectations by +67.57%.
Earnings released on 13 Aug 2021
EPS came in at -$0.45 falling short of the estimated -$0.36 by -25.00%, while revenue for the quarter reached $1.31m , meeting expectations.
Stock split effective on 20 Jul 2021
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
ARDX Stock Performance
Access detailed ARDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
